Showing results (1791-1800 of 1,881) with videos related to

Sort By:
Pageof 189
Immunotherapy|June 24, 2025
Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphomaM Oymanns, K Elsayad, L Wilms, et al.
Immunotherapy|June 30, 2025
NKT cells-a generalist in disease treatment and a new key to unlock immunotherapyGuanhua Lyu, Xu Wang, Xixi Li, et al.
Immunotherapy|June 27, 2025
Albumin-myosteatosis gauge as a prognostic biomarker in patients treated with immune checkpoint inhibitorsTaha Koray Sahin, Deniz Can Guven, Yakup Ozbay, et al.
Immunotherapy|December 2, 2025
Addressing social and economic disparities in triple-negative breast cancer immunotherapy: a U.S.-focused reviewIsmail Ajjawi, Maryam B Lustberg
Immunotherapy|January 15, 2025
Immunotherapy-related secondary hemophagocytosis in a glioblastoma patient: response to cytokine-directed therapyOzkan Alan, Mustafa Cem Bulbul, Mehmet Ali Enlice, et al.
Immunotherapy|December 9, 2024
Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysisJanet Roberts, Sara Barmettler, Jenna Murray, et al.
Immunotherapy|September 3, 2024
Immunotherapy and transarterial embolization in patients with metastatic melanoma: a retrospective cohort studyLeila Haghani, Chenyang Zhan, Hooman Yarmohammadi, et al.
Immunotherapy|September 11, 2024
Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicityDimitrios Bafaloukos, Ioanna Gazouli, Aikaterini Bousmpoukea, et al.
Immunotherapy|August 19, 2024
Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysisAlexander B Karol, Yu Fujiwara, Tyler D'Ovidio, et al.
Immunotherapy|November 26, 2024
Identifying risk factors and biomarkers for severe CIP in lung cancer patients- a retrospective case series studyGuixian Wu, Jingjing Qu, Jing Zheng, et al.
Pageof 189